HIV Infection Clinical Trial
Official title:
A Randomized Trial of Interleukin-2 Therapy in HIV-Infected Patients
Certain patients who are participating in NIH protocols involving interleukin-2 (IL-2)
therapy for HIV disease may be requested to have the following changes or additions to their
study protocol:
- 3-day subcutaneous (sc) IL-2 administration: Patients currently receiving IL-2
intravenously (injections through a vein) may switch to subcutaneous administration
(injections under the skin). Injections are given twice a day for 3 to 5 days (one
treatment cycle), with cycles repeated no more often than every 8 weeks.
- Home treatment of sc IL-2: Home administration of IL-2 injections involves less
frequent data and safety monitoring and no medical evaluations at the Clinical Center
except at the beginning of each cycle. Participants will receive IL-2 cycles on the
same schedule they followed in their original protocol. They will be seen at the
Clinical Center at regularly scheduled follow-up visits between cycles and for a
medical evaluation and blood drawing before the start of each cycle to determine the
safety of administering the next cycle. During the home cycle, the patient's case
manager or other team member will place monitoring telephone calls on days 2 and 4 of
the cycle and again a week later. The timing and number of these calls may change
depending on the findings of ongoing assessments of their usefulness. Patients will be
required to notify the study team promptly of complications or other problems that
develop with therapy.
- Stored specimens and HLA testing: Stored blood and tissue samples from patients will be
used for future research on HIV, AIDS and related medical conditions, and the immune
system. The samples may be labeled with no identifying information, with identifying
information, such as the patient's name, or with a code that only the study team can
link to the patient. Some of the blood drawn may be used for HLA typing, a genetic test
of markers of the immune system. Usually used to match bone marrow or organ
transplants, HLA type might also be used to try to identify factors associated with the
progression of HIV disease or related conditions. Determining HLA type is also
necessary to be able to perform certain research studies.
- Tonsillar biopsy: Examination of tonsil tissue may provide information on the effects
of IL-2 on the immune system and the expression of HIV. Patients in the randomized IL-2
study (93-CC-0113) may have tonsillar biopsies done up to three times-soon after
enrollment, after month 4, and after month 12. Patients in the open IL-2 study
(91-CC-0143) would have procedures no more often than every 3 months, with the
following exception: patients in either study who are willing to have repeat biopsies
performed during IL-2 therapy will have the procedure done up to three times during a
round of IL-2: before Il-2 therapy, day 2-3 or IL-2 therapy, and day 4-6 of IL-2
therapy, if the sequential biopsies can be safely performed. The area to be biopsied
will be numbed with a local anesthetic and 1 to 2 small pieces of tissue will be
biopsied.
- Skin biopsy: Examination of skin tissue may help to explain how IL-2 causes changes in
the skin. Biopsies will be obtained from areas of the skin that have been affected by
IL-2 as well as from normal, unaffected areas for comparison. Patients with Kaposi
sarcoma will also have biopsies of normal skin to allow comparison with IL-2-induced
changes in the Kaposi sarcoma lesions. The areas to be biopsied will be numbed with
local anesthetic and a 2-mm (1/10th-inch) piece of skin will be biopsied from each
site.
Status | Completed |
Enrollment | 60 |
Est. completion date | March 2002 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Patients must have documented HIV infection (ELISA and Western blot positive). Patients must be 18 years or older. Patients must have CD4 count greater than 200 cells/mm(3). Patients must have clinical laboratory values Grade 0 or 1. Patients must not have therapy with corticosteroids, chemotherapy, or experimental therapy in the prior 4 weeks. Patients must have a negative urine pregnancy test (women of childbearing potential). Patients with prior IL-2 therapy will be excluded. Patients with malignancy other than Kaposi sarcoma will be excluded. Patients with Kaposi sarcoma are eligible, but must not have received systemic therapy for KS within 4 weeks prior to study entry. Patients with history of prior AIDS-defining opportunistic infection will be excluded. Patients with active substance abuse which may affect patient safety or compliance will be excluded. Patients exhibiting psychiatric disturbance or illness, which in the assessment of the protocol team may affect patient safety or compliance will be excluded. Patients with significant cardiac, pulmonary, thyroid, kidney, rheumatologic, or CNS disease will be excluded. Patients with hypertension requiring anti-hypersensitive therapy will be excluded. Pregnant or lactating patients or patients of childbearing potential, will be excluded, unless they use effective contraception. Patients unwillingness to comply with current NIH Clinical Center guidelines concerning appropriate notification by an individual of current or ongoing sexual partners and/or needle-sharing partners regarding his or her HIV seropositivity and the risk of transmission of HIV infection will be cause for exclusion. |
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | National Institute of Allergy and Infectious Diseases (NIAID) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Vetto JT, Seipp CA, Rosenberg SA. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer. 1986 Dec 15;58(12):2764-72. — View Citation
Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol. 1991 Apr;9(4):694-704. Review. — View Citation
Smith KA. Interleukin-2: inception, impact, and implications. Science. 1988 May 27;240(4856):1169-76. Review. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
Active, not recruiting |
NCT02663856 -
My Smart Age With HIV: Smartphone Self-assessment of Frailty
|
||
Completed |
NCT02659306 -
Metformin Immunotherapy in HIV Infection
|
Phase 1 | |
Completed |
NCT02663869 -
Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
|
||
Completed |
NCT02846402 -
Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda
|
N/A | |
Completed |
NCT02921516 -
Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings
|
N/A | |
Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
Active, not recruiting |
NCT02302950 -
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
|
N/A | |
Terminated |
NCT01902186 -
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
|
Phase 4 | |
Completed |
NCT02269605 -
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment
|
Phase 1 | |
Completed |
NCT01830595 -
Lactoferrin Treatment in HIV Patients
|
Phase 2 | |
Completed |
NCT01852942 -
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
|
Phase 2 | |
Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
Completed |
NCT02118168 -
Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002
|
N/A | |
Completed |
NCT02525146 -
Birmingham Access to Care Study
|
N/A | |
Completed |
NCT02527135 -
Text Messaging to Improve HIV Testing Among Young Women in Kenya
|
N/A | |
Active, not recruiting |
NCT02602418 -
Neural Correlates of Working Memory Training for HIV Patients
|
N/A | |
Completed |
NCT01702974 -
Immune Reconstitution in HIV Disease (IREHIV)
|
Phase 2 |